YARS2
Basic information
Region (hg38): 12:32727490-32755897
Links
Phenotypes
GenCC
Source:
- myopathy, lactic acidosis, and sideroblastic anemia 2 (Definitive), mode of inheritance: AR
- myopathy, lactic acidosis, and sideroblastic anemia 2 (Strong), mode of inheritance: AR
- myopathy, lactic acidosis, and sideroblastic anemia (Supportive), mode of inheritance: AR
- myopathy, lactic acidosis, and sideroblastic anemia 2 (Moderate), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Myopathy, lactic acidosis, and sideroblastic anemia 2 | AR | Cardiovascular; Hematologic | Individuals may develop transfusion-dependent sideroblastic anemia in infancy; Surveillance for cardiovascular manifestations may allow early medical interventions | Cardiovascular; Hematologic; Musculoskeletal | 20598274; 22504945; 24344687; 24430573 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (240 variants)
- Inborn_genetic_diseases (64 variants)
- Myopathy,_lactic_acidosis,_and_sideroblastic_anemia_2 (38 variants)
- Hereditary_Sideroblastic_Anemia_with_Myopathy_and_Lactic_Acidosis (14 variants)
- YARS2-related_disorder (14 variants)
- not_specified (13 variants)
- Myopathy,_lactic_acidosis,_and_sideroblastic_anemia (6 variants)
- Mitochondrial_disease (2 variants)
- Lethal_Encephalopathy (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the YARS2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_001040436.3. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 86 | 87 | ||||
missense | 10 | 126 | 148 | |||
nonsense | 7 | |||||
start loss | 0 | |||||
frameshift | 10 | 14 | ||||
splice donor/acceptor (+/-2bp) | 2 | |||||
Total | 18 | 15 | 130 | 95 | 0 |
Highest pathogenic variant AF is 0.000174081
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
YARS2 | protein_coding | protein_coding | ENST00000324868 | 5 | 28413 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.00e-11 | 0.155 | 125327 | 1 | 420 | 125748 | 0.00168 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.264 | 247 | 259 | 0.954 | 0.0000130 | 3074 |
Missense in Polyphen | 62 | 72.149 | 0.85934 | 874 | ||
Synonymous | -0.966 | 121 | 108 | 1.12 | 0.00000552 | 1013 |
Loss of Function | 0.629 | 18 | 21.1 | 0.852 | 0.00000126 | 205 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0144 | 0.0144 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000333 | 0.000326 |
Finnish | 0.00296 | 0.00296 |
European (Non-Finnish) | 0.000618 | 0.000615 |
Middle Eastern | 0.000333 | 0.000326 |
South Asian | 0.000261 | 0.000261 |
Other | 0.000490 | 0.000489 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr- AMP and then transferred to the acceptor end of tRNA(Tyr). {ECO:0000269|PubMed:15779907, ECO:0000269|PubMed:17997975}.;
- Disease
- DISEASE: Myopathy with lactic acidosis and sideroblastic anemia 2 (MLASA2) [MIM:613561]: A rare oxidative phosphorylation disorder specific to skeletal muscle and bone marrow. Affected individuals manifest sideroblastic anemia, progressive lethargy, muscle weakness, and exercise intolerance associated with persistent lactic acidemia. {ECO:0000269|PubMed:20598274, ECO:0000269|PubMed:22504945}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Aminoacyl-tRNA biosynthesis - Homo sapiens (human);tRNA Aminoacylation;Translation;Metabolism of proteins;Tyrosine metabolism;tRNA charging;Mitochondrial tRNA aminoacylation
(Consensus)
Recessive Scores
- pRec
- 0.285
Intolerance Scores
- loftool
- 0.846
- rvis_EVS
- -0.47
- rvis_percentile_EVS
- 23.43
Haploinsufficiency Scores
- pHI
- 0.109
- hipred
- N
- hipred_score
- 0.317
- ghis
- 0.587
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.992
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Yars2
- Phenotype
Gene ontology
- Biological process
- translation;tRNA aminoacylation for protein translation;tRNA aminoacylation;mitochondrial tyrosyl-tRNA aminoacylation
- Cellular component
- mitochondrion;mitochondrial matrix;cytosol;nuclear body
- Molecular function
- tRNA binding;RNA binding;tyrosine-tRNA ligase activity;protein binding;ATP binding;protein homodimerization activity;tyrosine binding